Filter Results
:
(623)
Show Results For
-
All HBS Web
(623)
- People (2)
- News (54)
- Research (442)
- Events (2)
- Multimedia (7)
- Faculty Publications (389)
Show Results For
-
All HBS Web
(623)
- People (2)
- News (54)
- Research (442)
- Events (2)
- Multimedia (7)
- Faculty Publications (389)
Kyle Schirmann
Kyle Schirmann is a doctoral student in the Strategy unit at Harvard Business School. His primary interests are science-based innovation in the Global South and the creative and cultural industries. Before joining HBS, Kyle worked as a software engineer at Bloomberg...
View Details
- Web
Winners & Runners-Up | New Venture Competition
Acillix will deliver on the promise of biotechnology by revolutionizing the water treatment industry with our patented, low cost, environmentally friendly process for water demineralization. Elective Medical Lending Boyd Bishop Simon...
View Details
John T. Gourville
John Gourville is the Albert J. Weatherhead, Jr. Professor of Business Administration at the Harvard Business School. He joined the HBS Marketing Unit in 1995 after receiving his Ph.D. at the University of Chicago in marketing and behavioral research. His most... View Details
- Web
Q&A with the HBS Armed Forces Alumni Association, MBA Class of 2023 - MBA
Blog Blog MBA Voices Filter Results Arrow Down Arrow Up Read posts from Author Alumni Author Career and Professional Development Staff Author HBS Community Author HBS Faculty Author MBA Admissions Author MBA Students Topics Topics 1st Year (RC) 2+2 Program 2nd Year...
View Details
- Profile
Prineeta Kulkarni
Prineeta Kulkarni originally "dreamed of becoming a scientist." She completed a dual biotechnology BS/MS at the University of Pune, but when it came time to launch her career, she shifted direction. "I wanted to see the...
View Details
- September 2010 (Revised July 2013)
- Case
Alnylam Pharmaceuticals: Building Value from the IP Estate
By: Willy C. Shih and Sen Chai
The learning objective of this case is to help students recognize the interplay between intellectual property (IP) rights and corporate strategy. We do this by examining what is a fairly atypical circumstance today in which a single firm is able to secure what it...
View Details
Keywords:
Patents;
Lawsuits and Litigation;
Rights;
Competitive Strategy;
Corporate Strategy;
Biotechnology Industry;
Biotechnology Industry;
United States
Shih, Willy C., and Sen Chai. "Alnylam Pharmaceuticals: Building Value from the IP Estate." Harvard Business School Case 611-009, September 2010. (Revised July 2013.)
- Web
Climate Impact - Business & Environment
production of next-generation ingredients. We leverage biotechnology as a scalable, sustainable alternative to industrial agriculture and recently launched Palmless , the platform for sustainable palm oil alternatives.” Sarah Wright MBA...
View Details
- 02 Dec 2002
- Research & Ideas
The Secret of How Microsoft Stays on Top
industry or the biotechnology industry? Both industries share similarities with software, in that firms codify their intellectual property into libraries that can be reused and extended over time. But do we observe the same dynamics in...
View Details
Keywords:
by Sean Silverthorne
- 12 Apr 2022
- Blog Post
The Many Languages of Medicine to Impact Care Delivery
their suffering is extremely compelling and was the catalyst for my pursuit of an MS/MBA in Biotechnology degree. As a joint degree student, I benefit from immersive case studies at HBS where my classmates and I are challenged to analyze...
View Details
- January 2001
- Case
Abgenix and the XenoMouse
By: Robert J. Dolan
Abgenix has a unique method for generating antibodies useful in treating a number of diseases, including cancer. In early 2000, the company's cancer has performed very well in animal testing and is moving to early stage human testing. Abgenix must decide whether to...
View Details
Keywords:
Product Development;
Marketing Strategy;
Health Testing and Trials;
Risk and Uncertainty;
Technological Innovation;
Innovation Strategy;
Science-Based Business;
Biotechnology Industry
Dolan, Robert J. "Abgenix and the XenoMouse." Harvard Business School Case 501-061, January 2001.
- October 2007 (Revised July 2013)
- Case
Vertex Pharmaceuticals and the Cystic Fibrosis Foundation: Venture Philanthropy Funding for Biotech
By: Robert F. Higgins, Sophie LaMontagne and Brent Kazan
In 2001, Vertex Pharmaceuticals Incorporated acquired the San Diego-based biotech company, Aurora Biosciences. The combination of Vertex's and Aurora's technologies would improve the flow of novel drug candidates into development. However, several questions related to...
View Details
Keywords:
Philanthropy;
Philanthropy Funding;
Innovation;
Funding Model;
Venture Capital;
Partners and Partnerships;
Financing and Loans;
Investment Funds;
Acquisition;
Philanthropy and Charitable Giving;
Biotechnology Industry;
Biotechnology Industry;
San Diego
Higgins, Robert F., Sophie LaMontagne, and Brent Kazan. "Vertex Pharmaceuticals and the Cystic Fibrosis Foundation: Venture Philanthropy Funding for Biotech." Harvard Business School Case 808-005, October 2007. (Revised July 2013.)
- 01 Oct 2021
- News
From Scholarship to Life-Saving Impact
focused on patients. “Patients and their families are at the center of why I want to be in the biotechnology space,” she concludes. “When you’re working on rare diseases, it’s hard not to feel like you’re making a difference.”
View Details
- 17 Sep 2021
- Research & Ideas
The Trial of Elizabeth Holmes: Visionary, Criminal, or Both?
Former Theranos employees began testifying this week against Elizabeth Holmes, the once-celebrated biotech’s founder and CEO, in a criminal trial that has Silicon Valley worried. In opening statements last week, federal prosecutors charged that Holmes and the company’s...
View Details
- Profile
Lena Licht
biotechnology despite lacking tangible business experience. I’ll be leaving with the confidence that I can now be a business leader and change maker within my industry, and I cannot wait to hit the ground running after graduation! How...
View Details
- 18 Nov 2002
- Research & Ideas
Where Morals and Profits Meet: The Corporate Value Shift
information technologies. Recent advances in biotechnology have raised ethical issues that have never before presented themselves. And globalization has given rise to cross-cultural dilemmas that just weren't a major part of the scene in...
View Details
Keywords:
by Carla Tishler
- December 2005 (Revised August 2006)
- Case
Amgen Inc.'s Epogen--Commercializing the First Biotech Blockbuster Drug
By: Felix Oberholzer-Gee and Dennis A. Yao
Amgen Inc.'s Epogen was the first biotech blockbuster drug. Epogen helped prevent anemia, a condition that leads to severe fatigue, increased risk of cardiovascular disease, and even death. At the time, the market for Epogen, which included dialysis patients and...
View Details
Keywords:
Health Care and Treatment;
Strategic Planning;
Competition;
Patents;
Innovation and Invention;
Biotechnology Industry;
Biotechnology Industry;
United States
Oberholzer-Gee, Felix, and Dennis A. Yao. "Amgen Inc.'s Epogen--Commercializing the First Biotech Blockbuster Drug." Harvard Business School Case 706-454, December 2005. (Revised August 2006.)
- November 2020
- Case
Valuing Celgene's CVR
By: Benjamin C. Esty and Daniel Fisher
When Bristol-Myers Squibb (BMS) acquired Celgene Corporation in November 2019, Celgene shareholders received cash, BMS stock, and a contingent value right (CVRs) that would pay $9 if the U.S. Food and Drug Administration (FDA) approved three of Celgene’s late stage...
View Details
Keywords:
Mergers and Acquisitions;
Value;
Valuation;
Judgments;
Decision Making;
Cash Flow;
Financial Instruments;
Cognition and Thinking;
Biotechnology Industry;
Biotechnology Industry;
United States
Esty, Benjamin C., and Daniel Fisher. "Valuing Celgene's CVR." Harvard Business School Case 221-031, November 2020.
- Web
Student Spotlight: 2023 HCC Co-Presidents Reflect on Their Time at HBS and the Current Health Care Systems - Blog: Health Supplement
life sciences. They complemented the case method with applied learning through projects and written assignments–for example, a mock diligence report for a biotechnology company. Most importantly, the professors were phenomenal; they...
View Details
- 12 Jun 2018
- Research & Ideas
In a Landscape of 'Me Too' Drug Development, What Spurs Radical Innovation?
portfolios. They examined all companies that held at least one drug patent on the market as of 2003. The researchers focused mainly on small-molecule drugs, not biologics. That’s because of how the compounds are structured chemically. The complicated chemical makeup of...
View Details